AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04336254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
Description: Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
Study NCT04336254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline injection (Placebo)
Description: Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
Study NCT00016289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given intraperitoneally
Study NCT00353275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Strict Glycemic control
Description: Blood glucose target range is 80-110 mg/dL.
Study NCT01681979 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate (with and without concurrent salmeterol)
Description: Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose.
Study NCT04300907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Infinity Therapy System
Description: Treatment with the Provant Infinity Therapy System, PEMF device
Study NCT03336645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP615
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Study NCT01029080 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: No interventions
Study NCT01895088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000 PDT
Description: Inlay implanted in cornea for improvement of near vision
Study NCT00758706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: oral tablet, 75 mg, twice daily during 6 weeks
Study NCT00758706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1236
Study NCT03232554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills
Description: Buxue Yimu Pills 12g pill by mouth, twice daily.
Study NCT03232554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills &Ferrous Sulfate
Description: Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
Study NCT03232554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate 0.3g tablet by mouth, three times daily
Study NCT02421770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamaemelum nobile 2%
Description: Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are
Study NCT02421770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01225237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: oral
Study NCT01225237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01743768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Treatment group (n=19), receiving the active drug substance.
Study NCT01743768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group (n=19), receiving placebo.
Study NCT02077660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Four green tea bags per day for 12 weeks
Description: Four green tea bags per day for 12 weeks
Study NCT02077660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4 daily placebo tea bags for 12 weeks
Description: 4 daily placebo tea bags for 12 weeks
Study NCT01643928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab-Pfizer (PF-05280586) x 3 courses
Description: 1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
Study NCT01643928 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-EU+ Rituximab-Pfizer x 2 Courses
Description: Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
Study NCT01643928 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-US + Rituximab-Pfizer x 2 Courses
Description: Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
Study NCT01222182 — intervention group
Intervention type: DRUG
Intervention: atorvastatin
Description: All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
Study NCT03976349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB094
Description: Administered as specified in the treatment arm.
Study NCT00353275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional Glycemic Control
Description: Blood glucose target range is 110-140 mg/dL.
Study NCT01591746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT01591746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
Study NCT00063934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT00063934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT00063934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01408303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil, 4g
Description: Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
Study NCT01408303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-carboxylic acids, 2g
Description: Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
Study NCT00736996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 - 45mg tablet daily for 6 months
Study NCT00736996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet daily for 6 months
Study NCT00736996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Exercise Training
Description: Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
Study NCT02736084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
Study NCT03272438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: Participants use an accelerometer to monitor their steps activity
Study NCT03272438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Participants use an accelerometer to monitor their steps activity
Study NCT03272438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step goal
Description: Participants are given a daily step goal to aim for
Study NCT03272438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step goal
Description: Participants are given a daily step goal to aim for
Study NCT03272438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consistent contexts
Description: Participants plan to take steps in contexts that are similar from day to day
Study NCT03272438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inconsistent contexts
Description: Participants plan to take steps in contexts that vary from day to day
Study NCT01817205 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE with Hyperthermia Treatment
Description: Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter.
Study NCT03647514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study NCT03647514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study NCT04000165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
Study NCT03926182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST2818 Tablets
Description: AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
Study NCT03926182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST2818 Tablets
Description: AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
Study NCT01201525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Description: Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
Study NCT01201525 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Part 2 of the surgical scar will serve as a within patient control.
Study NCT03976349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04345887 — intervention group
Intervention type: DRUG
Intervention: Spironolactone 100mg
Description: 2x100 mg spironolactone for 5 consecutive days
Study NCT04345887 — intervention group
Intervention type: DRUG
Intervention: Placebo oral tablet
Description: 2 x1 placebo tablet
Study NCT01408303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-carboxylic acids, 4g
Description: Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
Study NCT02162134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar free chewing gum
Description: Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
Study NCT02162134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugared chewing gum
Description: Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study NCT01610323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
Study NCT01610323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study NCT02172183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmacological treatment
Description: methylphenidate or atomoxetine
Study NCT02172183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group
Study NCT04150588 — intervention group
Intervention type: DRUG
Intervention: Efrin drops
Description: The amount that the eyelid rise after Erin drops before surgery
Study NCT04030884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey and water mixture
Description: 60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day.
Study NCT02270840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D
Description: Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
Study NCT02748616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
Study NCT02860273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen
Description: Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
Study NCT02860273 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treadmill
Description: Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
Study NCT02375646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02375646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMW Heparin
Study NCT01518621 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Whole brain radiation
Study NCT01518621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation plus erlotinib
Description: Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
Study NCT03412461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thought Spot
Description: Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
Study NCT03412461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource Pamphlet
Description: The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
Study NCT01875991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept via Autoinjector A
Description: Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
Study NCT01875991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept via Autoinjector B
Description: Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
Study NCT03380182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Band
Description: These bands use pressure to stimulate the P6 acupuncture point.
Study NCT03380182 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Band
Description: These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
Study NCT03679312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study NCT03679312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study NCT01445431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Virgin coconut oil applied to the test site twice daily for four weeks
Study NCT01445431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Oil
Description: Mineral oil applied to the test site twice daily for four weeks
Study NCT01836003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tokafatso programmatic intervention
Description: Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women
Study NCT05292430 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: collection of diseased and non-diseased tissue, blood, and other body fluids
Study NCT02190344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8-channel paddle coil
Description: MRI Coil
Study NCT02454322 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
Study NCT02837263 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning.
Study NCT02837263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study NCT05974865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Babies and Healthy Moms
Study NCT05974865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Basics Prenatal Guide
Study NCT02488473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 100 ug dexmedetomidine added to the ropivacaine nerveblock
Study NCT02488473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml Ropivacaine 5mg/ml
Study NCT02488473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml Ropivacaine 5mg/ml
Study NCT02488473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Placebo